Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis.

ABSTRACT: Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA). However, over time, ~40% of patients may experience therapeutic failure or drug toxicity. The genetic variability of the enzymes involved in the MTX metabolic pathway seem to serve an important role in the eventual therapeutic failure or drug toxicity. Depending on the enzymes affected, the toxicity or the therapeutic response may change. The present study reports some of the polymorphisms identified in enzymes in the MTX metabolic pathway that are present in a group of Colombian patients with RA, and assesses the associations of these polymorphisms with toxicity or therapeutic response to the medication. A total of 400 patients with RA were evaluated, of which

SUBMITTER: Londono J 

PROVIDER: S-EPMC7418498 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature